First corresponding paper is out! Thank you to @Jorge88382322 and @GiedreKrenciute for the beautiful imaging and brain tumor models, Lindsay Talbot for the stunning HALO assay, and @Kyttaro_Therapy for the mentorship and support. All made possible by @StJude and @StJudeResearch
Antibody S22019F Selectively Recognises KIR2DS1 and Enables Analysis of KIR2DS1+ NK Cells and T Cells @QuirinHammer@karolinskainst
https://t.co/GmCSBC9pv7
CD39+CD49a+CD103+ NK cells, elicited by epithelial tumor cell exposure, can control solid tumors in mice
https://t.co/TpcooLzLB9 @ScienceTM@JohnSunwooMD@StanfordMed
Congrats to Dept. of Molecular Medicine and Therapeutics (MMT), #PIIO member @PeterChockley on being featured in the @AACR Cancer Immunology (CIMM) Junior Investigator Profile! His lab is advancing next-generation #CAR designs & synthetic receptor engineering to enhance #NKcell & #Tcell #antitumor activity.
https://t.co/hOTcyB8xl3
The Sim lab has been hard at work and we’re proud to present our first paper.
We developed new methods to study peptide:KIR interactions.
Congratulations to star postdoc Tanusya Murali who led the project.
https://t.co/hN0fbGOSRx
🔬 Join us for a live webinar: “Cell Avidity Uncovers Novel KIR:HLA Binding — Predicting Patient Survival Post Stem Cell Transplant” with Dr. @PeterChockley
📅 November 19, 2025 | 4PM (EST)
🔗 Register now: https://t.co/JONaHjTuv0
#CellTherapy#NKcells#KIRHLA#StemCellTransplant #ImmunoOncology
Esther Obeng leads a research group focused on myelodysplastic syndromes (MDS) @EmoryMedicine. @JExpMed spoke with Esther about her career, how her patients inform her research, and more
#WomenInSTEM
https://t.co/OidzkpP9ua
The Foltz lab is growing! If you are interested in working on improving NK cell therapies for cancer, consider applying at: https://t.co/DjQaib0nz8 or reaching out to us at https://t.co/uaV443PUQA! @WashUDeptMed@WUSTLImmuno@SitemanCenter
I’m hiring a sr. bioinformatics research scientist in integrative analysis to perform data analysis and visualization, statistical analysis, experimental design, database development, mathematical modeling, and novel method development. Join the team. https://t.co/xWgc8MLsam
Come join my lab as a sr. scientist focused on applied integrative biology to develop and implement novel technical approaches for assaying single cell dynamics, high throughput functional screening, and high parameter molecular phenotyping. https://t.co/0YXuvzlePe #NowHiring
RNAseq is commonly performed. We compared N=30 wild-type Bl6 mice to an N=30 heterozygotic knockout with a phenotype, and then downsized. We found you need at least an N= 8-12 to avoid a >50% false positive rate. A 2nd line confirmed the finding.
https://t.co/wwKRUcdKmH
@jkagan1 Totally agree. 6week vs 8week old mouse can dictate tumor growth or rejection. I rarely accept a 5 week old mouse study as mildly relevant scientifically.
Join us for The International Conference on Cellular Immunotherapy in Pediatric Oncology (CIPO) at St. Jude in June 2024.
https://t.co/hOw2YsyWzl
@StJude@StJudeResearch@ASTCT@ThePTCTC